What's new? Log in Free sign up

Lipocine (LPCN) News and press releases

Company Profile

News

From Benzinga Pro

12 Health Care Stocks Moving In Friday's After-Market Session

12 Health Care Stocks Moving In Friday's Pre-Market Session

Lipocine Completes Enrollment Of LPCN 1148 Phase 2 Study For Decompensated Cirrhosis

Biotech, News, FDA, General

Top-line 24-week results from proof-of-concept study expected mid-2023 SALT LAKE CITY, Dec. 19, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company focused on treating Central Nervous

Lipocine Q3 EPS $(0.03) Up From $(0.04) YoY

Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.03) per share. This is a 25 percent increase over losses of $(0.04) per share from the same period last year.

Press releases

From Benzinga Pro

Lipocine to Present at Biotech Showcase

Company Management Will Also Host Meetings at LifeSci Partners Corporate Access Event SALT LAKE CITY, Jan. 5, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company focused on treating Central

Lipocine Completes Enrollment of LPCN 1148 Phase 2 Study for Decompensated Cirrhosis

Top-line 24-week results from proof-of-concept study expected mid-2023 SALT LAKE CITY, Dec. 19, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company focused on treating Central Nervous System

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2022

Earnings, Press Releases

SALT LAKE CITY, Nov. 9, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company focused on treating Central Nervous System ("CNS") disorders by leveraging its proprietary platform to develop